. This transformative approach allows for the creation of engineered systems that intelligently sense and respond to diverse environments, ultimately adding specificity and efficacy that extends beyond the capabilities of molecular-based therapeutics [3] [4] [5] [6] . One particular area of focus has been the engineering of bacteria as therapeutic delivery systems to selectively release therapeutic payloads in vivo [7] [8] [9] [10] [11] . Here we engineered a non-pathogenic Escherichia coli strain to specifically lyse within the tumor microenvironment and release an encoded nanobody antagonist of CD47 (CD47nb) 12 , an anti-phagocytic receptor that is commonly overexpressed in several human cancer types 13, 14 . We show that delivery of CD47nb by tumor-colonizing bacteria increases activation of tumor-infiltrating T cells, stimulates rapid tumor regression, prevents metastasis and leads to long-term survival in a syngeneic tumor model in mice. Moreover, we report that local injection of CD47nb-expressing bacteria stimulates systemic tumor-antigen-specific immune responses that reduce the growth of untreated tumors, providing proof-of-concept for an abscopal effect induced by an engineered bacterial immunotherapy. Thus, engineered bacteria may be used for safe and local delivery of immunotherapeutic payloads leading to systemic antitumor immunity.
The origins of cancer immunotherapy trace back to the pioneering work of William Coley, who observed tumor clearance in some patients that received injections of bacteria 15 -a result that has now been attributed to leukocyte activation [16] [17] [18] . Several studies have demonstrated that bacteria preferentially grow within tumor cores owing to the immunoprivileged nature of the often hypoxic and necrotic tumor microenvironment, and can locally affect tumor growth through the recruitment and activation of the immune system [19] [20] [21] [22] [23] . With the advent of synthetic biology over the past two decades and the development of numerous bacterial gene circuits 6, [24] [25] [26] [27] [28] , we reasoned that programming bacteria to controllably release recombinant immunotherapies could enable the local delivery of higher effective concentrations of therapy while preventing the toxicities observed following systemic delivery of identical or similar therapeutic agents.
To test this approach, we chose to target CD47, an anti-phagocytic receptor that is overexpressed in several human cancer types 13, 14, 29 . Recent studies have demonstrated that CD47 blockade not only increases phagocytosis of cancer cells but also promotes cross-presentation of tumor antigens to enhance priming of antitumor effector T cells in syngeneic mouse tumor models 12, [30] [31] [32] . However, as demonstrated in both preclinical models 33 and human trials 34, 35 , systemic CD47 blockade can result in anemia and thrombocytopenia due to the high expression of CD47 on red blood cells and platelets, respectively. To improve its therapeutic profile, a nanobody (a camelid single-domain antibody fragment) against CD47 with an approximately 200-fold higher binding affinity than commercially available anti-mouse CD47 monoclonal antibodies was recently developed and characterized 12 . This nanobody demonstrated mild effects as a monotherapy, potentially due to the lack of Fc-mediated effector function 33, 36 ; however, a notable therapeutic response was observed when used in combination with a tumor-specific antibody and systemic immunecheckpoint blockade. Here, we engineered an E. coli strain, which contained a synchronized lysis circuit (eSLC), that colonizes tumors and undergoes intratumoral quorum lysis to locally release an encoded nanobody antagonist of CD47 (eSLC-CD47nb) (Fig. 1a) . This system allows for the combined local delivery of an immunotherapeutic agent along with immunostimulatory bacterial lysis adjuvants to stimulate antitumor immunity and promote tumor regression.
To confirm expression and lysis-dependent release of CD47nb, we transformed non-pathogenic E. coli with a single plasmid that encodes the eSLC, as well as a stabilized plasmid that drives constitutive expression of a hemagglutinin (HA)-tagged variant of CD47nb (Extended Data Fig. 1 ). The SLC + strain grows and produces the quorum-sensing molecule acylhomoserine lactone through the expression of luxI and lyses at a critical threshold owing to the production of a bacteriophage lysis protein (ϕX174E), resulting in bacterial death and therapeutic release 8 (Fig. 1a) . As this gene circuit was previously tested using two plasmids of differing copy numbers 8 , we verified SLC-mediated lysis of eSLC-CD47nb E. coli using time-lapse microscopy of bacteria using an agar pad 37 . eSLCCD47nb grew, reached quorum and lysed over a 20-h time course, in contrast to non-SLC E. coli (SLC − ), which continuously grew and filled the field of view (Extended Data Fig. 2a) . Furthermore, we cultured SLC + and SLC − E. coli in lysogeny broth (LB) medium in a 96-well plate and measured the optical density at 600 nm (OD 600 ) over time. eSLC-CD47nb-expressing E. coli (SLC + ) exhibited multiple periodic dips in OD 600 , indicating rounds of synchronized lysis, whereas SLC − E. coli exhibited normal bacterial growth kinetics (Fig. 1b) . After verifying the synchronized lysis behavior, we evaluated lysis-mediated release of CD47nb in batch cultures. Immunoblots of log-phase bacterial cultures indicated that eSLCCD47nb bacteria released significantly higher levels of HA-tagged CD47nb into culture supernatants than control CD47nb-HA Letters Nature MediciNe bacteria without SLC (Extended Data Fig. 2b ), suggesting that CD47nb release is enhanced by eSLC.
To verify that the bacterially produced nanobody functionally binds to CD47, A20 lymphoma cells-which are known to express CD47 30 -were incubated with a fixed concentration of fluorescein isothiocyanate (FITC)-labeled anti-mouse CD47 monoclonal antibody (clone miap301) and serial dilutions of bacterial lysates from eSLC-CD47nb or eSLC bacteria containing an empty vector ( Fig. 1c and Extended Data Fig. 2c ). We observed a progressive reduction in CD47 staining when cells were incubated with lysates from bacteria expressing CD47nb, suggesting that bacterially produced CD47nb could outcompete miap301 binding to CD47 on the surface of A20 cells. We additionally cloned a C-terminal 6×His-tagged variant of CD47nb and purified recombinant CD47nb (rCD47nb) by nickel-affinity chromatography. Similarly, we observed a progressive reduction in FITC fluorescence when A20 cells were co-incubated with increasing concentrations of rCD47nb and a fixed concentration of FITC-labeled miap301 (Extended Data Fig. 2d) .
Moreover, we evaluated the ability of eSLC-CD47nb to induce A20 tumor cell phagocytosis by bone-marrow-derived macrophages (BMDMs) (Fig. 1d and Extended Data Fig. 2e ). As expected, treatment with anti-CD47 monoclonal antibody resulted in a 60% increase in phagocytosis (Extended Data Fig. 2e ) and treatment with eSLC lysate alone led to an increase in phagocytosis of tumor cells by 50%. Notably, eSLC-CD47nb lysate treatment led to a 90% increase in phagocytosis compared to baseline, indicating that eSLC-CD47nb enhances phagocytosis of tumor cells by macrophages in a combinatorial, dose-dependent mannerthrough CD47 blockade as well as TLR agonism due to bacterial lysis adjuvants ( Fig. 1d and Extended Data Fig. 2e ). Overall, these results indicate that eSLC-CD47nb releases CD47nb in a lysisdependent manner and that CD47nb can induce phagocytosis of tumor cells by BMDMs in vitro.
We next sought to evaluate the clinical efficacy of eSLC-CD47nb bacteria in a syngeneic mouse model. BALB/c mice bearing A20 tumors in both hind flanks received intratumoral injections of PBS, eSLC bacteria or eSLC-CD47nb bacteria. Although administration of control eSLC alone initially slowed tumor growth, likely owing to the activation of innate immune cells by bacterial products released upon quorum lysis, final tumor volumes were not statistically different from PBS-treated mice. By contrast, administration of eSLC-CD47nb resulted in rapid and durable clearance of established A20 tumors within approximately 10 days of commencing therapy ( Fig. 2a and Extended Data Fig. 3a,b) . In contrast to animals that received intratumoral injections of PBS or control eSLC bacteria, liver metastases were rarely observable in mice treated with eSLC-CD47nb at 30 days after treatment (Fig. 2b) . Notably, approximately 80% of mice treated with eSLC-CD47nb survived more than 90 days (Fig. 2c ) and surviving mice were resistant to rechallenge by subcutaneous injection of 10 × 10 6 A20 cells (Fig. 2d) , whereas naive mice that received the same batch of A20 cells developed tumors within a week of injection.
Subsequently, we explored the importance of therapeutic delivery of individual components of our quorum-lysis system ( Fig. 2e and Extended Data Fig. 3d ). First, we evaluated efficacy of CD47 blockade by intraperitoneal delivery of miap301 with or without intratumoral injection of eSLC. Neither group demonstrated significant efficacy in comparison to treatment of eSLC alone in an A20 mouse model. Although mice treated intratumorally with recombinant CD47nb or sonicated eSLC-CD47nb bacterial lysates exhibited slower tumor growth in comparison to mice treated with eSLC, complete tumor regression was only observed upon treatment with live, eSLC-CD47nb-expressing bacteria ( Fig. 2e and Extended Data Fig. 3d ). These data collectively suggest that continuous SLC-mediated intratumoral release of CD47nb is essential to therapeutic efficacy.
To assess the broader applicability of our approach, we also examined efficacy by intravenous administration as well as by using additional mouse tumor models. Significant therapeutic efficacy was observed when eSLC-CD47nb was intratumorally injected in other syngeneic mouse models, such as in mice bearing triplenegative breast cancer cells (4T1, Fig. 2f and Extended Data Fig. 4b ) and melanoma cells (B16-F10, Fig. 2h and Extended Data Fig. 4c ). Lung metastases were notably reduced in mice that received eSLCCD47nb in the 4T1 model (Fig. 2g) . We additionally explored the ability of eSLC-CD47nb to safely target and treat tumors through systemic intravenous delivery. In comparison to mice who received a systemically delivered anti-CD47 antibody (miap301), mice injected with intravenous eSLC-CD47nb showed significantly slower tumor growth ( Fig. 2i and Extended Data Fig. 5a ). Following treatment, bacteria localized exclusively to tumors compared to the liver, spleen and kidney (Extended Data Fig. 5b ). Bacterial therapy was well-tolerated by animals, with no significant differences in body weight between treatment groups observed throughout the observation period after both intratumoral and intravenous delivery (Extended Data Figs. 3c, 4a, 5c ). Overall, these results indicate that eSLC-CD47nb can safely promote local tumor regression while also preventing metastasis, suggesting the induction of systemic antitumor immunity that is likely mediated by tumor-specific T cells. 
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Recent studies have highlighted the importance of antigenpresenting cells and indicated that effector T cells are indispensable for anti-CD47-mediated clinical responses 30, 31 . We reasoned that local inflammation induced by bacterial lysis coupled with localized blockade of CD47 on tumor cells would increase tumor cell phagocytosis and tumor antigen presentation, thereby enhancing Fig. 3a . b, Quantification of metastatic nodules present in livers on day 30 after bacterial therapy (n = 5 per group, ****P < 0.0001, unpaired two-tailed t-test). c, Kaplan-Meier survival curves for A20-tumor-bearing mice (n = 5 per group, ***P = 0.0004, log-rank (Mantel-Cox test)). d, Mice that had completely cleared A20 tumors were rechallenged with 10 × 10 6 A20 cells on day 90 after initial treatment. Naive mice received 5 × 10 6 A20 cells in each flank (n = 4 mice per group). e, When A20 tumor volume reached 100-150 mm 3 , mice received intratumoral (i.t.) injections of eSLC (n = 4 tumors), eSLC-CD47nb bacterial lysate (n = 6 tumors), rCD47nb (50 µg, n = 8 tumors) or eSLC-CD47nb (n = 4 tumors), or intraperitoneal (i.p.) injections of anti-CD47 monoclonal antibody (clone miap301, 400 µg, n = 6 tumors) alone or in combination with intratumoral eSLC (n = 4 tumors) for a total of four doses every 3-4 days. Tumor growth curves (****P < 0.0001, ***P = 0.0002, *P = 0.0162, NS, not significant (P > 0.05); two-way ANOVA with Tukey's multiple comparisons test). 
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+ macrophages 3 days after commencing therapy (Extended Data Fig. 6a ), suggesting an increase in the antigen-presentation ability of tumor macrophages at early time points. Additionally, on day 8, we observed a decline in SIRPα + macrophages within the tumor (Extended Data Fig. 6b) . Previous studies have shown that lipopolysaccharide exposure leads to SIRPα downregulation on macrophages in vitro 38 . We hypothesized that combined release of lysis adjuvants and lack of SIRPα downstream signaling following CD47 blockade may lead to reduced surface expression of SIRPα on tumor-associated macrophages. Additionally, immunophenotyping of tumors treated with eSLCCD47nb revealed increased proliferation of both FOXP3 − CD4 + and CD8
+ T cells (Fig. 3a,b ) in comparison to tumor-bearing mice treated with eSLC bacteria. Furthermore, tumor-infiltrating FOXP3 − CD4 + T cells from eSLC-CD47nb-treated tumors produced significantly higher levels of IFNγ following ex vivo restimulation with phorbol myristate acetate (PMA) and ionomycin (Fig. 3c) . Although we observed a trend towards higher IFNγ levels in CD8 + T cells (Extended Data Fig. 6h ), we observed markedly elevated levels of intratumoral granzyme B + CD8 + T cells (Fig. 3d) as well as other parameters of adaptive immune activation (Extended Data Fig. 6c-g ). Additionally, these T cell responses appeared to be tumor-antigen-specific, as overnight in vitro coculture of irradiated A20 cells with splenocytes derived from mice treated with eSLC-CD47nb led to robust secretion of IFNγ (Extended Data Fig. 7) . Interestingly, mice treated with miap301 exhibited no elevated IFNγ response in comparison to those receiving eSLC-CD47nb. These data suggest that eSLC-CD47nb not only supports the activation and proliferation of intratumoral T cells, but also lead to the induction of systemic anti-A20 memory T cell responses.
Durable remission from cancer requires not only elimination of treated tumors, but also systemic antitumor immunity for the clearance of distant metastases. On the basis of our observation that eSLC-CD47nb enhances the effector function of tumor-infiltrating T cells within treated tumors, we examined whether eSLC-CD47nb could delay growth of untreated tumors. Mice injected with A20 tumors on both flanks were treated with eSLC-CD47nb in a unilateral fashion (Fig. 4a) . Whereas control eSLC bacteria had no effect on the growth of untreated tumors, treatment of the primary tumor with eSLC-CD47nb substantially slowed the growth of untreated tumors on the opposing flank (Fig. 4b,c and Extended Data Fig. 8a ). To further quantify this effect, we computed the mean growth rates (mm per day) of treated compared to untreated tumors by calculating the slopes in tumor volume trajectories for each mouse (Fig. 4d ). These data indicated that tumors of eSLC-CD47nb-treated mice showed decreased growth rates for both treated and untreated tumors compared to controls. It has been shown that an intratumorally released nanobody does not lead to systemic CD47 blockade 33 , providing evidence that the SLC-produced nanobody likely does not disseminate to the opposing, untreated tumor. However, we considered the possibility that eSLC-CD47nb bacteria injected into the primary tumor migrated through systemic circulation to seed the untreated lesion. We intratumorally injected a luminescent strain of SLC + E. coli (E. coli NisLux) 39 into a single tumor and performed in vivo imaging over 5 days. In comparison to a SLC − strain for which luminescence continuously increased over time, SLC + E. coli NisLux exhibited fluctuations in luminescence, indicating in vivo lysis behavior (Extended Data Fig. 8b,c) . Importantly, the luminescent signal was limited to the injected lesion and the signal was undetectable in the untreated tumor or other organs, indicating that an adaptive immune response may be mediating this abscopal effect. In support of this hypothesis, flow cytometry analysis of lymphocytes isolated from untreated tumors of mice of which primary tumors were injected with eSLC-CD47nb showed increased frequencies of activated (Extended Data Fig. 9e) and proliferating (Fig. 4e) CD8 + T cells as well as a trend towards increased frequencies of proliferating FOXP3 − CD4 + T cells (Extended Data Fig. 9a ). Additionally, we observed a significantly higher percentage of FOXP3 − CD4 + and CD8 + T cells producing IFNγ following ex vivo restimulation with PMA and ionomycin (Extended Data Fig. 9b,c) . We directly assessed the reactivity of T cells in untreated tumors to an endogenous tumor antigen. Tumor-infiltrating lymphocytes were stimulated with an H-2Kd-restricted peptide (A20-Id, DYWGQGTEL), corresponding to the unique idiotype of the antibody expressed by A20 lymphoma cells, which has previously been shown to activate tumor-antigen-specific CD8 + T cells 40 . Following ex vivo stimulation with A20-Id peptide, we observed a significantly higher frequency of IFNγ +
CD8
+ T cells in mice treated with eSLC-CD47nb in comparison to mice treated with eSLC or PBS (Fig. 4f) . As further confirmation of the specificity of this assay, the frequency of IFNγ
+ T cells (Extended Data Fig. 9f ) was unchanged-consistent with this peptide being MHC class I restricted. These data suggest that treatment with eSLCCD47nb enhances tumor-antigen-specific CD8 + T cell activity in the untreated tumor.
To further exclude the possibility of trafficking by bacteria, we assessed the biodistribution of SLC + E. coli at multiple time points after unilateral intratumoral injection. Plating of homogenized 
+ T cells (n = 5 per group, **P = 0.0011, unpaired two-tailed t-test). All data are shown as mean ± s.e.m.
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Nature MediciNe tumors and organs revealed that bacterial growth remained restricted to treated tumors and no bacteria could be cultured from untreated tumors or livers and spleens of treated mice above the limit of detection (approximately 1 × 10 3 colony-forming units (CFU); Fig. 4g ). Furthermore, SLC-mediated CD47nb release appeared to be necessary for the induction of a potent abscopal effect. Although eCD47nb (a SLC − strain that constitutively produces CD47nb) administration slowed the growth of treated lesions in comparison to treatment with eSLC ( Fig. 4h and Extended Data Fig. 10a ), it exhibited a much weaker effect on untreated tumors in comparison to eSLC-CD47nb (Fig. 4i and Extended Data Fig. 10b ). Taken together, these results demonstrate that the engineered quorum-lysis immunotherapeutic delivery system can generate potent, tumor-specific adaptive immune responses that operate systemically to clear distant tumor lesions.
This approach couples the inherently immunostimulatory nature of bacterial lysis products from programmable bacteria with potent nanobody-mediated blockade of an anti-phagocytic receptor. We observed enhanced proliferation and activation of tumor-infiltrating lymphocytes, leading to the induction of durable and systemic anti-tumor immunity. Our results suggest that localized, lysis-mediated release of the anti-CD47 nanobody confers multiple advantages over conventional systemic monoclonal antibody therapy-intratumoral delivery of a nanobody by . h,i, Tumor growth curves of treated and untreated A20 tumors following unilateral intratumoral injections of eSLC, eCD47nb or eSLC-CD47nb every 3-4 days for a total of four doses (n = 4 per group, ***P = 0.001, ****P < 0.0001, two-way ANOVA with Tukey's multiple comparisons test). All data are mean ± s.e.m. Tumor growth curves of tumors from individual mice are shown in Extended Data Fig. 10a,b. Letters Nature MediciNe eSLC increases the local concentration of immunotherapy while simultaneously preventing systemic toxicity. Local treatment with eSLC-CD47nb promotes the induction of systemic antitumor immune responses that are not observed after treatment with an anti-CD47 monoclonal antibody. Finally, the ease of engineering bacteria to express additional immunotherapeutic nanobodies and/or cytokines, opens the possibility of evaluating combinations of several other immunotherapeutics that have exhibited systemic toxicity, but may be safe and effective when delivered intratumorally using eSLC. Our system allows for the delivery of immunotherapeutics in a spatiotemporally defined manner and permits delivery within diverse solid tumor settings. Moreover, owing to the observed abscopal effect, we provide a future strategy for treating metastatic lesions through the injection of accessible primary tumors.
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Methods Strains and plasmids. Plasmids were constructed using Gibson assembly or standard restriction enzyme-mediated cloning methods. The pSC01 SLC plasmid was constructed by first amplifying a region that contained the constitutively expressed luxR gene and phage lysis gene, ϕX174E under the control of the luxI promoter from a pZA35E plasmid 8 . Next, this region was cloned into a pTD103-luxI plasmid 27 using the AvrII site. The pSC02 therapeutic plasmid was constructed by cloning a gBlock (IDT) encoding a tac promoter and an E. coli codon-optimized sequence for the A4 anti-CD47 nanobody 12 with an C-terminal HA tag into the multiple cloning site of a pAH162 plasmid 41 . Additionally, two stabilizing elements, the hok/sok system 42 and alp7 partitioning system 43 were introduced into pSC02 to minimize plasmid loss in vivo. pSC01 and pSC02 were transformed into chemically competent E. coli Pir1 + (Invitrogen). eSLC strains were grown in LB medium with 50 µg ml −1 kanamycin (pSC01) and 100 µg ml −1 tetracycline (pSC02) along with 0.2% glucose at 37 °C for under 12 h in a shaking incubator. Glucose was added to reduce expression from the Lux promoter and prevent lysis in vitro. The pSC04 protein expression plasmid was constructed by cloning a gBlock (IDT) that encodes an E. coli codon-optimized sequence for the A4 anti-CD47 nanobody 12 with a C-terminal 6×His tag into the multiple cloning site of an 1-thiod-galactopyranoside (IPTG)-inducible pET vector containing ampicillin resistance (100 µg ml −1 ). pSC04 was transformed into NiCo21(DE3) E. coli (NEB).
Characterization of the SLC. To validate SLC function, SLC + and SLC − E. coli were inoculated in LB medium, which contained the appropriate antibiotics, and diluted 1:10. Samples were grown at 37 °C in a round-bottom 96-well plate in a shaking Tecan plate reader. The OD 600 was recorded every 10 min for 20 h. Agar pads were prepared according to previous protocols 37 . SLC + and SLC − E. coli were inoculated in LB medium, which contained the appropriate antibiotics, and grown to mid-log phase. They were diluted 1:100 and grown under agar pads at 37 °C and imaged using a Nikon Ti-E microscope equipped with an Okolab stage top incubator.
Bacterial nanobody characterization.
For purification of rCD47nb, pSC04-containing NiCo21(DE3) E. coli were grown at 37 °C to an OD 600 of approximately 0.8 and induced with 1 mM IPTG for 20 h at 30 °C. Cells were centrifuged at 4,000 r.p.m. for 10 min. After resuspension in lysis buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, pH 8.0) and sonication, lysates were spun at 10,000 r.p.m. for 30 min at 4 °C. The supernatant was loaded on to Ni-NTA (Qiagen) resin and washed in wash buffer (35 mM imidazole), followed by elution in 250 mM imidazole. The elutions were then dialyzed in PBS using regenerated cellulose dialysis tubing (3,500 Da MWCO) and the solution was filtered through a 0.2-µm filter to remove any residual debris and stored at −80 °C.
Overnight cultures of E. coli containing pSC01 and pSC02 were grown in appropriate antibiotics and 0.2% glucose. A 1:100 dilution into LB with antibiotics was made the following day and bacteria were grown in a shaking incubator at 37 °C. OD 600 was measured every 30 min until the OD 600 of lysing strains began to fall, indicating lysis. At this point, OD-normalized bacteria were spun down at 3,800 r.p.m. and supernatants were filtered through a 0.2 µm filter. Cell pellets were mechanically lysed by 3-4 freeze-thaw cycles. Supernatants and lysates were separated by SDS-PAGE followed by immunoblotting with rat anti-HA (Sigma) antibody to evaluate the presence of rCD47nb in culture fractions. To verify binding of bacterially produced nanobody to CD47 on tumor cells, serial dilutions of bacterial supernatants from SLC bacteria with or without pSC02 or rCD47nb were co-incubated with FITC-labeled anti-CD47 antibody in the presence of A20 tumor cells for 1 h and FITC fluorescence was measured by flow cytometry.
In vitro phagocytosis. Overnight cultures of E. coli containing pSC01 and pSC02 were grown in appropriate antibiotics and 0.2% glucose. A 1:100 dilution into LB with antibiotics was made the following day and bacteria were grown to mid-log phase in a shaking incubator at 37 °C. Bacteria were pelleted at 3,800 r.p.m. and lysed by sonication. To obtain eSLC and eSLC-CD47nb lysates, sonicates were spun at 10,000 r.p.m. for 5 min and supernatants were filtered through a 0.2-µm filter to remove any residual debris. Collected BMDMs were detached and seeded onto a transparent 96-well tissue culture plate at 5 × 10 4 cells per well. A20 tumor cells were incubated for 10 min with 5 µM Vybrant DiI solution (Invitrogen). Labeled A20 cells were pretreated with serial dilutions of bacterial lysates (eSLC or eSLCCD47nb) or with anti-CD47 monoclonal antibody, isotype antibody or PBS. After 3.5 h co-incubation of labeled, pretreated A20 cells and BMDMs, residual A20 cells were washed and BMDMs were stained with NucBlue. Multiple random fields were imaged for each replicate using a Nikon Ti-E microscope. The ratio of DiI + BMDMs to total NucBlue + BMDMs was counted for each field to score phagocytosis.
Animal models. All animal experiments were approved by the Institutional Animal Care and Use Committee (Columbia University, protocols AC-AAAN8002 and AC-AAAZ4470). The protocol requires animals to be euthanized when the tumor burden reaches 2 cm in diameter or after recommendation by the veterinary staff. Mice were blindly randomized into various groups. Animal experiments were performed on 4-8-week-old female BALB/c mice or C57BL/6 mice (Taconic Biosciences) with bilateral subcutaneous hind-flank tumors from A20 mouse lymphoma cells (ATCC), 4T1-luciferase mammary carcinoma cells (ATCC, luciferized by stable plasmid transfection) or B16-F10 melanoma cells. Cells were injected subcutaneously at a volume of 100 μl per flank, with each implant consisting of 5 × 10 6 cells (BALB/c, A20), 10 6 cells (BALBc, 4T1) or 5 × 10 5 (C57BL/6, B16-F10). Tumors were grown to an average volume of approximately 100-200 mm 3 before treatment with bacterial strains. Tumor volume was calculated by measuring the length and width of each tumor using calipers, where V = length × width 2 × 0.5 as previously calculated 30 . For all tumor growth experiments, a minimum of four mice per group were used. The growth in mm per day was computed by taking the difference between tumor volumes at adjacent time points for a particular animal. Values were computed as the mean ± s.e.m.
Bacterial administration for in vivo experiments. Bacterial strains were grown overnight in LB medium, which contained the appropriate antibiotics and 0.2% glucose. A 1:100 dilution into medium with antibiotics was started the day of injection and grown to an OD 600 of approximately 0.1. Bacteria were spun down and washed three times with sterile PBS before injection into mice. Intratumoral injections of bacteria were performed at a concentration of 5 × 10 8 CFU ml −1 in PBS with a total volume of 20-40 μl injected per tumor. Tail-vein (intravenous) injections of bacteria were performed at a concentration of 5 × 10 7 CFU ml −1 in PBS with a total volume of 100 µl injected per mouse.
Biodistribution and in vivo bacterial dynamics. Following treatment with 10 7 SLC + E. coli, tumors, spleen and liver were weighed and homogenized using a gentleMACS tissue dissociator (Miltenyi Biotec; C-tubes). Homogenates were serially diluted and plated on LB-agar plates at 37 °C overnight. Colonies were counted (limit-ofdetection 10 3 CFU g −1
) and computed as CFU g −1 of tissue. To determine in vivo dynamics of SLC + and SLC − E. coli, 10 7 SLC + or SLC − E. coli NisLux (genomic expression of luxCDABE cassette) were injected unilaterally into hind-flank tumors. The luminescent signal was measured at multiple time points over 4 days with an in vivo imaging system after injection of bacteria to follow dynamics.
Flow cytometry. Tumors were extracted for immunophenotyping on day 3 or day 8 after the initiation of bacterial therapy. Myeloid and lymphoid subsets were isolated from tumor tissue by mechanical homogenization of tumor tissue followed by digestion with collagenase A (1 mg ml
; Roche) and DNase I (0.5 µg ml ; Sigma-Aldrich) and ionomycin (1 nM; Calbiochem) in the presence of GolgiPlug (brefeldin A). To measure tumor-antigen-specific production of cytokines by T cells, cells were stimulated for 5 h with A20-Id (DYWGQGTEL) peptide (GenScript) for 5 h in the presence of GlogiPlug (brefeldin A). Following extracellular staining with the aforementioned antibodies, intracellular staining was performed using anti-CD3 (Tonbo), anti-TCRβ (BD), anti-CTLA4 (eBioscience), anti-FOXP3 (eBioscience), anti-Ki-67 (Thermo), anti-granzyme-B (Biolegend) antibodies and cytokines (anti-IL-17 (eBioscience), anti-TNF (eBioscience), anti-IFNγ (Tonbo) antibodies). Cells were fixed using the FOXP3/transcription factor staining buffer set (Tonbo) as per the manufacturer's protocol. Samples were analyzed using a BD LSRFortessa cell analyzer.
Statistical analysis. Statistical tests were calculated in GraphPad Prism v.7.0 and v.8.0. The details of the statistical tests carried out are indicated in the respective figure legends. Where data were approximately normally distributed, values were compared using either a Student's t-test or one-way ANOVA for single variables, or using a two-way ANOVA for two variables with Tukey's correction for multiple comparisons. For Kaplan-Meier survival experiments, we performed a log-rank (Mantel-Cox) test. Mice were randomized into different groups before experiments.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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